Global Titans Brings the World’s First NFT Pay-Per-View Sports Event Live From the Helipad of Burj Al Arab, on May 14th, 2022
25.4.2022 17:40:00 EEST | Business Wire | Press release
ROQUMedia:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220425005564/en/
Mayweather Global Titans Poster (Photo: AETOSWire)
FLOYD MAYWEATHER:
https://twitter.com/FloydMayweather/status/1517594581373648896?s=20&t=dEEnqLrQWsybIa81CA-JJA
Global Titans Fight Series announced the WORLD’S FIRST EVER NFT SPORTS event will give access to an exclusive livestream pay-per-view for NFT ticket holders. The Global Titans NFT tickets are considered a historic moment, where sports and tech fans take a giant leap forward, changing the way one interacts with live entertainment.
The NFT ticket will give access to watch Global Titans Dubai live online on May 14th, where an epic night of boxing on the helipad of the iconic Burj Al Arab Jumeirah hotel. The spectacular event boasts an explosive line-up including star champions Floyd Mayweather, Anderson Silva and many more.
A landmark moment for international sports, fans buying the NFT will also acquire a special Global Titans NFT ticket, that is highly collectable. More than an event ticket, NFT technology provides buyers with unique features such as future access, rewards and more – all that increase the value of its ownership long after the event.
Developing special technologies, ROQUMedia and Yakomoz Events, the founders of Global Titans, have teamed up with Web3 experts, MintGate for this NFT. Buyers will be able to watch the livestream of these inaugural fights directly from anywhere in the world without requiring access codes or passwords. NFT owners can simply connect their crypto wallets (such as MetaMask) for instant access.
Additionally, owners of this NFT will be able to unlock Limited Edition 3D collectibles, special video content and official media from the event.
There are two Global Titans NFT tickets now available to the public.
- 80,000 collectible NFTs with PPV access in the Polygon Matic or payable by credit card.
- Currently 10 highly exclusive ringside seat NFTs are available to attend this event in person.
Seat to attend the event and collectable NFT ticket Pay-Per-View livestream are available at www.globaltitans.com
“MintGate is hyper-focused on making digital ownership accessible to anyone in the world,” said Jonathan Dunlap (CEO). “To further this mission, we launched a revolutionary way to purchase a NFT directly with a credit card,” continued Matt Hoffman (CSO).
Robert Quirke, ROQUMedia (CEO) stated: “For many people, this will be the first time they will buy an NFT. We made sure to provide them with great value, by including exciting digital assets that can be traded and combined to watch the Floyd Mayweather fight livestream online. The live event on May 14th will be known as an international turning point where live sports and entertainment embraced the next generation of technology. The PPV tickets use the Polygon Blockchain & MATIC, as this offers fans the lowest gas fees, making them significantly more environmentally friendly.”
GLOBAL TITANS
Global Titans Dubai is the first in series of special boxing and MMA events which will be staged at iconic locations across four continents. Each main event is broadcast globally, featuring champion fighters and exclusive collectable NFT tickets.
Seat to attend the event and collectable NFT ticket Pay-Per-View livestream: www.globaltitans.com
MINTGATE
MintGate is a proven web3 platform for building membership-based communities and elevating the relationship between people and the brands they care about. We bring people closer to the future by unlocking the value of digital ownership.
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220425005564/en/
Contact information
KATCH INTERNATIONAL
Sharanya Paulraj
Email:
sharanya@katchthis.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom